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The appropriateness and timing of mitral valve surgery in patients with advanced heart failure and severe mitral
regurgitation remains controversial. Recent surgical results provide evidence for beneficial effects on left ventric-
ular remodeling and functional capacity. Given the absence of randomized trials comparing the outcomes of mi-
tral valve surgery to medical therapy, however, clinical decision making regarding surgery for these fragile pa-
tients poses a dilemma to thoughtful clinicians. This paper reviews the pathophysiology of mitral regurgitation in
heart failure and proposes an integrated approach to management. (J Am Coll Cardiol 2010;55:271–82)
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phe appropriateness of mitral valve (MV) surgery for
atients with severe mitral regurgitation (MR) and ad-
anced heart failure (HF) remains embroiled in controversy
1). Proponents and skeptics both have highlighted unre-
olved issues including the approach to “functional” MR
2–5), the benefit of repair of moderate ischemic MR in
atients undergoing coronary artery bypass grafting (6,7),
itral valve repair (MVR) versus MV replacement (6), and
he long-term outcomes of surgery for functional MR
ompared with medical therapy (8,9). Until the Cardiac
urgical Clinical Trials Network reports the results of
ngoing randomized, prospective trials (10), clinical deci-
ion making devolves to existing observational series and
necdotal experience.
This paper reviews salient aspects of MR pathophysiol-
gy and the experience in MV surgery in advanced HF. It
oncludes with a suggested approach to the management of
his challenging patient group.
mportance of MR in HF
ignificant MR occurs in 30% of patients with myocardial
nfarction (11) and in 35% to 50% of patients with chronic
F (12). Observational studies report an approximately
wofold increase in mortality with significant MR with
erhaps a lesser contribution in patients with advanced HF
7,13). Increasing MR is associated with proportionally
ncreasing mortality among patients with chronic HF (5).
he presence of MR doubles mortality in patients after
rom *Vanderbilt University, Nashville, Tennessee; †University of Pennsylvania,
hiladelphia, Pennsylvania; and ‡Massachusetts General Hospital, Boston,
assachusetts. Dr. Acker is a consultant with Acorn Cardiovascular.t
Manuscript received February 27, 2009; revised manuscript received August 7,
009, accepted August 10, 2009.ost-myocardial infarction and decreases survival in graded
ashion in patients undergoing PCI (14).
efinition of severity. Severe MR corresponds to 50%
f total left ventricular (LV) stroke volume (the regurgitant
raction) ejected into the left atrium through the regurgitant
rifice (Table 1) (15). Moderate and mild degrees of MR
orrespond to regurgitant fractions of 30% to 50% and
30%, respectively. Flow through the regurgitant orifice
rea depends on the orifice area, the square root of the
ressure gradient between the left ventricle and the left
trium, the duration of systolic flow, and a derived “dis-
harge” coefficient. The regurgitant orifice area may be
ynamic in response to developed LV pressure, LV end-
iastolic volume, and LV geometry (11). For example, MR
s less during midsystole, when maximal LV closing forces
ccasion greater MV coaptation than during the early and
ate phases of systole.
ormal MV Function
ormal MV function depends on the structural integrity
nd coordinated action of the 6 anatomic components of the
itral apparatus (Fig. 1): the MV annulus, anterior and
osterior mitral leaflets, chordae tendinae, anterolateral and
osteromedial papillary muscles, subtending myocardium at
he insertion of papillary muscles, and overall ventricular
eometry. The MV leaflet closure at the normal coaptation
ites depends on the various forces that act upon these
omponents: annular contraction, leaflet tethering forces
ransduced via the chordae, papillary muscles, and subtend-
ng myocardium, and the “closing forces” transduced by LV
ontraction. As stated by Levine and Schwammenthal (11),
he “equilibrium” of the mitral leaflets in normal “closed”
osition throughout systole is determined by the balance of
hese forces acting upon these anatomic components.
r
a
o
a
p
v
b
b
a
“
(
m
v
i
c
t
r
f
t
i
E
N
f
e
C
d
M
p
t
m
r
f
o
s
d
t
(
s
d
i
M
I
e
c
M
r
(
m
p
d
l
V
c
l
c
t
i
S
a
p
i
v
c
t
i
p
M
h
(
m
s
(
v
m
M
272 Di Salvo et al. JACC Vol. 55, No. 4, 2010
Mitral Valve Surgery in Advanced HF January 26, 2010:271–82Features of normal anatomy
and function are worth additional
brief comment. The posterior one-
third of the mitral annulus is con-
tractile, and provides an important
“cincturing” of the annulus during
systole. The cross-sectional tissue
area of the mitral leaflets is approx-
imately twice that required to span
the normal annulus orifice—thus,
limited “redundancy” exists assum-
ing normal annular dimensions.
Although preservation of chordal
continuity is important for overall
ventricular function, selective
transsection of basal chordae may
not be associated with ventricular
dysfunction and provides partial
leaflet untethering (16).
Pathophysiology of MR
MR may result from structural or
functional abnormalities of the
components of the mitral appa-
atus and/or the forces that act upon them (Fig. 1). In the
bsence of intrinsic abnormalities of the tissue composition
r anatomy of the MV apparatus, ventricular remodeling
ccounts for most instances of severe MR (2,11). Because
rogressive ventricular remodeling also results from chronic
olume overload in severe MR (17,18), significant MR
egets progressive ventricular remodeling, which in turn
egets progressive MR (17).
Several authors have emphasized that in patients with
dvanced LV remodeling and HF, severe MR represents a
ventricular disease” masquerading as a valvular disease
2,11). This realization poses a critical and challenging
anagement issue. Although relief of MR unloads the left
entricle, if the stage of LV adverse remodeling is irrevers-
ble, MR correction may not provide significant benefit. It is
ritical, therefore, to undertake MV surgery only for pa-
ients in whom some cardiac plasticity (19) or “reverse
emodeling viability” yet remains. As discussed in the
ollowing text, it has proven difficult with existing diagnostic
ools to conclude which ventricles possess reverse remodel-
ng viability.
tiology of MR
onischemic MR. “Functional” MR results primarily
rom tethering of the MV leaflets due to ventricular remod-
ling, specifically, increased LV dilation and sphericity (11).
ontractile dysfunction alone in the absence of ventricular
ilation or increased sphericity does not result in significant
R (20). Ventricular dilation and increased sphericity affect
apillary muscle displacement and a relative lateral redirec-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft surgery
CRT  cardiac
resynchronization therapy
HF  heart failure
LV  left ventricular
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
MR  mitral regurgitation
MRI  magnetic resonance
imaging
MV  mitral valve
MVA  mitral valve
annuloplasty
MVR  mitral valve repair
NHBLI  National Heart,
Lung, and Blood Institute
NYHA  New York Heart
Associationion of the tethering forces normally perpendicular to the Ritral annular plane. This redirection of tethering forces
esults in incomplete leaflet coaptation.
In ventricular dysfunction, tethering length (the distance
rom papillary muscle tips to anterior mitral annulus) is the
nly independent predictor of MR (20). Increased LV
phericity also results in greater MR (21,22). Annular
ilation and reduced closing forces primarily “modify”
ethering, but are not the predominant mechanisms of MR
11). In the chronically volume overloaded ventricle, con-
titutive increases in LV wall stress eventually effect a
ecrease in contractility (23) and a corresponding reduction
n the annular and closing forces that may otherwise lessen
R due to tethering alone.
schemic MR. In animal models, papillary muscle isch-
mia alone does not result in significant MR (24). Although
ontroversial, the most important mechanism of ischemic
R is likely MV leaflet tethering due to post-infarction
emodeling induced displacement of the papillary muscles
25). This most commonly occurs with posterior displace-
ent of the posteromedial papillary muscle in inferior or
osterior transmural infarctions. Annular dilation and re-
uced closing forces due to reduced contractility also likely play
esser, primarily “modifying” roles in ischemic MR (11).
entricular remodeling. Chronic severe MR incurs in-
reased ventricular wall stress due to increased diastolic
oading (15). The left ventricle adapts during a typically long
ompensated state marked by eccentric ventricular hyper-
rophy and enhanced ventricular compliance. Synthesis of
ncreased sarcomeres in series effects eccentric hypertrophy.
uch “elongated” myocytes preserve ventricular compliance
nd accommodate increased pre-load with preservation of
re-load recruitable reserve.
After a variable period of time (as little as 2 to 4 months
n animal models but probably longer in humans), the left
entricle progresses through this transitional stage to a
hronically decompensated stage (2). During this transi-
ional stage, several lines of evidence demonstrate alterations
n myocyte and extracellular matrix biology demarking the
hysiological adaptive limits of eccentric hypertrophy (15).
yocardial gene expression shifts from a compensatory
ypertrophic paradigm to a fibrotic and apoptotic paradigm
17,26). In the chronically decompensated state in animal
odels, significant myocyte “drop-out” with hypertrophy of
urviving myocytes and increased interstitial fibrosis occur
Fig. 2) (23). Although the determinants of progressive
entricular contractile dysfunction and noncompliance are
ore complex than simply myocyte drop-out and matrix
itral Regurgitation Severity by EchocardiographyTable 1 Mitral Regurgitation Severity by Echocardiography
Echo Parameter Mild Moderate Severe
Vena contracta width (cm) 0.3 0.3–0.69 0.7
Regurgitant volume (ml/beat) 30 30–59 60
Regurgitant fraction (%) 30 30–49 50
Effective regurgitant orifice area (cm2) 0.2 0.2–0.39 0.40eprinted with permission from Mehra et al. (5).
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January 26, 2010:271–82 Mitral Valve Surgery in Advanced HFbrosis, eventually a terminally remodeled, hypocontractile,
oncompliant ventricle evolves.
herapeutic Options
edical therapies. To the extent that medical therapies
ffect reserve geometric remodeling (reduction in LV dila-
Figure 1 Mechanisms of MR
(Left) Balance of forces acting on mitral leaflets in systole. (Right) Effect of p
infarction; light shading indicates normal baseline. Reprinted with permission
tricle; MR  mitral regurgitation.
Figure 2 Histological Changes in a Canine Model of Chronic Se
Reprinted with permission from Carabello et al. (23).ion or sphericity), they should restore proportionally the
ormally perpendicular orientation of the papillary muscles
o the annulus and thereby reduce MR. By reducing LV
oad, various intravenous and oral vasodilators (nitroprus-
ide, angiotensin-converting enzyme inhibitors, hydral-
zine, and isosorbide dinitrate) in concert with loop diuret-
y muscle (PM) displacement. Dark shading indicates inferobasal myocardial
evine and Schwammenthal (11). AO  aorta; LA  left atrium; LV  left ven-
Mitral Regurgitationapillar
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Mitral Valve Surgery in Advanced HF January 26, 2010:271–82cs may, in selected patients, reduce MR by as much as 1 to
echocardiographic grades (27,28) and substantially reduce
ena contracta width (29).
The antiapoptotic and fibrosis inhibition effects of neu-
ohormonal antagonists (angiotensin-converting enzyme
nhibitors, angiotensin receptor-blockers, beta-blockers, al-
osterone antagonists) have been well described for chronic
F. There is only modest evidence to date that renin-
ngiotensin system inhibition provides substantial benefit
eyond vasodilation per se in severe MR (2,5). There are
ompelling experimental and human data, however, that
eta-adrenergic blockade attenuates LV remodeling in
hronic severe MR. Atenolol attenuates the increase in LV
ass, lowers LV filling pressures, improves contractile
erformance in both the intact heart and isolated cardio-
yocytes, increases myofibril cell content, and improves
yocardial histology in a canine model of severe MR (Fig.
) (30). Carvedilol reduces the MR ratio (MR jet area/left
trium area) by 20% via reverse remodeling (31). There is
s yet no conclusive evidence that neurohormonal antago-
ists specifically improve clinical outcomes once severe
entricular dysfunction ensues.
Positive intravenous inotropes reduce MR. In an echo-
ardiographic series, 61% of patients with LV ejection
raction 50% had improvement in MR grade during
obutamine echocardiography (32). Inotropes, however, are
ot feasible for chronic use, and play a limited role in MR
anagement outside of the acute hospital setting. Intra-
ortic balloon counterpulsation may reduce MR acutely
nd prove life saving in patients with acute severe mitral
egurgitation. Ventricular assist devices also reduce or
bolish MR.
ardiac resynchronization therapies (CRTs). CRT re-
uces functional MR acutely (33,34) and chronically in
elected patients by 1) decreasing effective regurgitant orifice
rea by as much as nearly 50%; 2) increasing LV dP/dt (ratio
f change of ventricular pressure to change in time) and LV
losing forces; and 3) partially reversing LV remodeling and
educing MV apical tethering (35,36). Chronically, more
xtensive LV remodeling from CRT appears to lead to
roportionally greater reductions in MR. More than half of
he responders to CRT sustain reductions of at least 1 grade
n MR for at least 6 months (37). Kanzaki et al. (34) have
hown that realignment of contractile timing of the papil-
ary muscles is partially responsible for a significant reduc-
ion in MR severity in the setting of left bundle branch
lock and cardiac dyssynchrony. Significant MR recurs if
ffective CRT is interrupted or discontinued.
urgical Options
urrent consensus indications for MR surgery. The
urrent updated American College of Cardiology/American
eart Association valve disease guidelines (1) include an
ppropriately cautious but generally supportive recommen-
ation for consideration of MV surgery in patients with pdvanced HF, but only if MVR or MV replacement with
hordal sparing are options. The authors conclude that
. . .even though such a patient is likely to have persistent
V dysfunction, surgery is likely to improve symptoms and
revent further deterioration of LV function. . .” (1).
rior published studies. To date, there has been neither
) a randomized prospective trial of MV surgery compared
ith medical therapy in patients with severe MR and
dvanced HF; 2) a trial of different repair techniques; nor
) a comparison of MVR versus MV replacement. The
ational Heart, Lung, and Blood Institute (NHBLI) Car-
iothoracic Surgical Trials Network is currently conducting
prospective, randomized multicenter clinical trials of MV
urgery: 1) coronary artery bypass graft surgery (CABG)
lone versus CABG plus MVR in moderate MR; and
) mitral repair versus chordal-sparing MV replacement in
atients with severe ischemic MR (10). Many experienced
urgeons at high-volume centers currently perform isolated
V surgery for severe, symptomatic ischemic MR in
atients with prior CABG and no available targets for redo
evascularization. In many such patients, symptoms improve
ven without a readily demonstrable improvement in LV
unction. It is hoped that the NHLBI trials will inform
ecision making in this difficult patient group.
Prior published series of MV surgery in patients with
dvanced HF are summarized in Table 2 (9,38–48). Since
tudies to date are retrospective, observational, and mostly
ingle center, they all suffer from potential referral, selection,
scertainment, and reporting biases and limited generaliz-
bility. Studies to date have mingled patients with ischemic
nd nonischemic cardiomyopathy, and patients undergoing
imultaneous coronary artery bypass surgery. Most studies
ave reported center-specific techniques for repair.
Despite these limitations, review of the cumulative pub-
ished experience supports a few broad conclusions. First,
or carefully selected patients with advanced HF, MV
urgery (particularly MV annuloplasty) appears reasonably
afe, with reported 30-day mortality rates in the majority of
tudies between 1.6% and 5%. Second, most series have
eported modest but statistically significant reverse remod-
ling (increases in left ventricular ejection fraction [LVEF],
V end-diastolic volume, LV end-systolic volume, and LV
phericity indexes) and more striking improvements in
unctional class and quality of life. Some, but not all, studies
ave reported improved exercise capacity. Third, with cur-
ent annuloplasty techniques, moderate or greater MR
ccurs in as many as 35% of patients within 1 year of surgery
49–51). Lee et al. (52) have examined mechanisms of
ecurrent MR after MVR for nonischemic cardiomyopathy.
ecurrent (2 MR) was associated with greater distal
itral anterior leaflet angle, greater coaptation depth and
enting area, larger LV volumes, and poorer LVEF. Mitral
nnular dimension and post-operative exaggeration in pos-
erior leaflet angle were similar. The authors conclude that
osterior leaflet tethering is invariable after MV annulo-
lasty and post-operative mitral competence is highly de-
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January 26, 2010:271–82 Mitral Valve Surgery in Advanced HFendent on distal anterior leaflet mobility. Reverse remod-
ling, particularly of the posterior wall, is associated with
onger repair durability after annuloplasty (49,53–56). Use
f rigid rather than flexible annuloplasty rings is associated
ith a lower likelihood of recurrent MR requiring reopera-
ion (57). Fourth, the repair versus replacement risk-
enefit ratio remains unclear in advanced HF patients
iven the higher failure rate but lower risk of MVR
elative to the lower failure rate but higher risk of MV
eplacement. Fifth, the mortality benefit of mitral valve
nnuloplasty (MVA) or MVR in either ischemic or
onischemic HF compared with conventional medical
nd device therapies is not yet established.
A few studies are worthy of detailed comment. Wu et al.
9) performed a propensity analysis on a selected subset of
26 consecutive patients (mean age 65.5  9.6 years, LV
nd-diastolic diameter [LVEDD] 65 8 mm, LVEF 23
%) with severe MR and advanced HF who underwent
VA (undersized annuloplasty ring) at the University of
ichigan between 1995 and 2002. Thirty-day mortality
as 4.8%. MVA treated as a time-dependent covariate was
ot an independent predictor of the combined clinical
utcome of death, LV assist device implantation, or United
etwork for Organ Sharing status 1 listing for cardiac
ransplantation (Fig. 3). Freedom from the combined end
oint was 50% at 5 years.
Limitations of this study include the time period (1995 to
002) and lack of information regarding follow-up inter-
entions. During the study period, a variety of annuloplasty
ings (including flexible and partial rings) were used, poten-
Figure 3 Survival for MVA Versus Medical
Therapy in the University of Michigan Cohort
Survival for mitral valve annuloplasty (MVA) group (dotted line) versus medical
therapy (solid line) in the University of Michigan cohort. Reprinted with permis-
sion from Wu et al. (9).P
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Mitral Valve Surgery in Advanced HF January 26, 2010:271–82ially modifying the outcome of MVR. There was signifi-
ant underutilization of beta-blockers (33%), spironolactone
15%), and implantable cardioverter-defibrillators (18%) in
he MVA patients compared with contemporary practice.
he proportion of patients in either group after surgery who
eceived interventions subsequently shown to impact mor-
ality in advanced HF (e.g., beta-blockers, implantable
ardioverter defibrillators, biventricular permanent pace-
akers) is not provided. Despite these limitations, the study
as sounded a cautionary note that the mortality benefit for
VA may not be pronounced.
In an uncontrolled observational study, Mihaljevic et al.
58) evaluated the effect of MV annuloplasty for moderate
o severe MR among patients undergoing CABG. From
991 to 2003, 390 patients with 3/4 MR underwent
ABG alone (n  100) or CABG plus MVA (n  290).
roups were propensity matched for extent of coronary
rtery disease, demographics, and regional wall motion.
ew York Heart Association (NYHA) functional class
mproved in both groups and remained improved at 5-year
ollow-up; 25% of both groups had NYHA functional class
II/IV symptoms. One-, 5-, and 10-year survival rates did
ot differ: 88%, 75%, and 47% after CABG alone and 92%,
4%, and 39% for CABG and MVR, respectively (Fig. 4).
imitations included the nonrandomized assignment to
urgical therapy, lack of echocardiographic data on all
atients who underwent isolated CABG, lack of contem-
orary HF therapy, and absence of pre-operative myocardial
iability measures or post-operative remodeling parameters.
he high recurrence rate cited in this series may be
ttributable in part to use of partial Cosgrove annuloplasty
ings.
Several large observational series of patients with isch-
mic MR undergoing repair or replacement with and
ithout CABG have been reported. The Dion group (59)
eported that CABG combined with MVR employing a
estrictive annuloplasty ring resulted in low mortality, im-
rovement in symptoms, reverse remodeling, and minimal
R recurrence at 4 years. These favorable results were
eported only if the pre-operative LVEDD was65 mm by
chocardiography. Some series from high-volume surgical
enters have reported no difference in mortality between
VR and MV replacement in patients with ischemic MR
60), including no difference in outcome between MVR and
V replacement in older class IV patients with ischemic
R (61).
A more optimistic tone for surgery for nonischemic MR
as sounded from the trial designed to evaluate the efficacy
f the Acorn CorCap (Acorn Cardiovascular, St. Paul,
innesota), a LV passive restraint device. Acker et al. (38)
eported the outcome of 193 patients enrolled in the MVA
r MVR stratum of the Acorn study, 102 randomly allo-
ated to MVA alone and 91 to MVA plus CorCap. Repair
as performed via an undersized MV annuloplasty ring in
4.2%, and MVR in 15.8%. Mean LVEDD was 69.7 8.8
m, LVEF 23.9  8.9%, peak VO2 14.1  4.3 (g·kg1·min1, and NYHA functional class II, III, and IV
ere 23.3%, 71.55%, and 5.2% of subjects, respectively. The
emographics were unusual for a HF cohort: 54.4% were
emale, 39.9% were nonwhite minority patients, and 93.8%
ad nonischemic cardiomyopathy. The MR severity graded
to 4 by the core echocardiography laboratory was found in
.4%, 10.6%, 23.3%, 25.9%, and 32.8%, respectively.
The 30-day mortality was 1.6% and survival at 1 and 2
ears was 86.5% and 85.2%, respectively (Fig. 5). There was
ignificant evidence of reverse remodeling: MR grade de-
reased 2.66 to 0.59 (p  0.0001) at 18 months, and at 24
onths, LVEF increased by 4.1% (p  0.03), mean
phericity index increased by 0.197 (p  0.0001) and mean
V mass decreased 72.81 g/m2 (p  0.0001). Compared
ith patients having MVR alone, MVR plus CorCap
atients had greater improvements in sphericity index and
ystolic and diastolic ventricular volumes, but not MR grade
Figure 4 Survival After CABG Plus
MV Annuloplasty Versus CABG Alone
Survival after coronary artery bypass graft surgery (CABG) plus mitral valve (MV)
annuloplasty versus CABG alone. Reprinted with permission from Mihaljevic et
al. (58). MR  mitral regurgitation.62). The NYHA functional class declined from a baseline
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January 26, 2010:271–82 Mitral Valve Surgery in Advanced HFf 2.82 to 2.25 at 24 months (p  0.0001). There was no
ignificant change in peak VO2 at 12 months. In summary,
he investigators concluded that there is “clear benefit to the
urgical elimination of mitral regurgitation” and that the
orCap device appeared to provide “significant additional
enefit,” with incremental improvements in remodeling. A
ubsequent report showed sustained benefits in indices of
everse remodeling at 3-year follow-up, with a crude mor-
ality rate of27% (62,63). Five-year follow-up results from
he MR subgroup of the Acorn trial have been presented but
ot yet published (64). At 5 years, only 19% of patients
videnced recurrence of 2 MR. Evidence of significant
emodeling persisted and included the significant improvement
f LVEF noted at 18 months. Because only 7% of these
atients had ischemic MR, these favorable Acorn trial results
ertain to patients with nonischemic MR.
As compelling as these findings are, there are several
aveats. First, the degree of MR was 3 to 4 in only 60% of
he population, and 23% of the subjects were in NYHA
unctional class II. Despite the evidence of reverse remod-
ling and improvement in quality of life, there was no
ignificant increase in peak VO2 (perhaps due to beta-
locker therapy for 80.3% of the study population). The
nvestigators specifically excluded from the study patients
ith any 4 of the following criteria: severe LV enlargement
LVEDD 80 mm), marked exercise limitation (peak VO2
13 ml·kg1·min1), systolic BP 80 mm Hg, atrial
brillation, HF duration 8 years, exercise-induced in-
rease in systolic blood pressure 10%, 6-min walk test
350 m, prior cardiac surgery, blood urea nitrogen 100
g/dl, and cachexia (5). Despite these caveats and selective
nclusive criteria, the low perioperative risk and 3-year
utcomes are encouraging and provide some “proof of
rinciple” evidence for LV passive restraint devices (8).
urrent Unresolved Controversies
election of candidates. While it is clear that the failing
entricle would benefit from relief of severe MR, unan-
wered questions remain regarding appropriate patient se-
Figure 5 2-Year Survival for Acorn Study Cohort
Reprinted with permission from Acker et al. (38).ection, acceptable perioperative mortality, and long-term Lurvival benefit (Table 3) (4). As the thoughtful clinician
ormulates a recommendation, 2 pre-operative candidate
election issues in particular consistently arise: 1) minimi-
ation of perioperative risk; and 2) LV reverse remodeling
iability. Candidates should have favorable surgical and
edical considerations (Table 3), and resultant low pre-
icted perioperative morbidity and mortality (ideally 2%)
5). Long-term reduction in morbidity and mortality should
e at least comparable to that with current medical and
evice therapy. One would, therefore, preferentially recom-
end MV surgery for advanced HF patients with some
vidence—however indirect by existing tools—of LV re-
erse remodeling viability (Table 3).
linical Outcomes
urgical. From existing surgical series, patients with con-
urrent CABG and MVR tend to fare better than patients
ndergoing MVR alone, although the operative risk is
igher (6% to 12%) (11). In studies to date, post-infarction
atients who undergo MV surgery for severe MR with
imultaneous LV remodeling procedures (LV aneurysm
lication, excision, or exclusion) appear to have more
urable relief of MR, although the complexity of these
ombined operations increases risk, and this approach has
ot been prospectively compared with MV surgery alone.
atients with passive, reversible pulmonary artery hyperten-
ion due to chronic severe MR generally fare well after
uccessful MV surgery. However, patients with fixed pul-
onary vascular resistance, nonreversible pulmonary artery
ypertension, and chronic advanced RV dysfunction are
igh, if not prohibitive, risk candidates for MV surgery.
atients who have had prior cardiac surgery are at inherently
igher risk. Other potential clinical factors increasing risk
rom the Acorn trial were discussed in preceding text.
bbreviated Criteria for Selectionf Appropriate Operative CandidatesTable 3 Abbrevi ted riteria for Selectionof Appropriate Operative Candidates
Favorable surgical considerations
Coronary artery disease and concurrent revascularization
Ventricular reconstruction (e.g., Dor)
Reversible pulmonary hypertension
No prior operations
Favorable medical considerations
NSR (or likelihood of restoration)
“Tolerance” of reasonable doses of vasodilators and beta-blockers
Preservation of renal function
Absence of hyponatremia
Absence of refractory right heart failure
Absence of cachexia
Favorable LV reverse remodeling viability
Absence of severe ventricular dilation (LVEDD 80 mm)
Lower sphericity index
Preservation of LV torsion
Presence of contractile reserve
Beneficial response to cardiac resynchronizationV  left ventricle; LVEDD  left ventricular end-diastolic diameter; NSR  normal sinus rhythm.
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Mitral Valve Surgery in Advanced HF January 26, 2010:271–82edical. The following clinical features are associated with
orse prognosis in advanced HF: persistent resting tachy-
ardia, low proportional pulse pressure, tolerance of low
oses or recent reduction in doses of vasodilators or beta-
lockers, hyponatremia, elevation of blood urea nitrogen
nd serum creatinine in the absence of intrinsic renal
isease, prolonged QRS duration, cardiac cachexia, and
efractory right ventricular failure (65). These clinical fea-
ures also belie a higher surgical risk and likely lesser degree
f LV reverse remodeling viability.
everse remodeling viability. Although uncommonly
vailable as routine measures, a higher LV sphericity index,
ess preservation of LV torsion during systole, and greater
egrees of myocardial fibrosis likely belie more limited
everse remodeling viability. Left ventricle sphericity can be
alculated by echocardiography at end diastole and end
ystole as the volume of the left ventricle divided by the
olume of a sphere with a diameter equal to the left ventricle
ongest axis in the apical view (49). Left ventricle torsion
ay be measured by magnetic resonance imaging (MRI)
tagging” techniques. Gadolinium-enhanced MRI can
uantitate myocardial fibrosis (66).
The degree of LV contractile reserve as assessed by
xercise or inotropic stimulation is a predictor of LV
unction after MVR in minimally symptomatic patients
67), acute-onset and chronic symptomatic HF (68), and
ortic stenosis with ventricular dysfunction (69,70). As such,
ssessment of LV contractile reserve should likely play a
ore important role in the recommendation of MV surgery
n advanced HF. Failure to respond to CRT despite
cceptable LV lead configuration may also be an indirect
marker” of limited LV contractile reserve and/or remodel-
ng viability.
uggested Approach to the Management of Severe MR in AdvanceTable 4 Suggested Approach to the Management of Severe MR
1. Optimize medical therapy
Angiotensin-converting enzyme inhibitor/angiotensin receptor-blocker, beta-blocke
hydralazine-isosorbide dinitrate
Define adequacy of medical therapy by cardiac catheterization in selected instanc
Ensure compliance with medical therapy and lifestyle accommodations
2. Evaluate for revascularization in patients with coronary artery disease
3. Provide CRT
Indications: LV ejection fraction 35%, QRS interval 120 ms, New York Heart A
Reassess clinical response and MR severity
4. Reconfirm the severity of MR
“Definitive” imaging modality after optimizing medical therapy, revascularization,
5. For patients who remain intolerably symptomatic, define perioperative risk and su
Ideally, perioperative risk should be 2% on the basis of composite medical and
Ideal candidates will have heart failure duration 5 years, resting heart rate 10
pressure, serum sodium 135 mmol/dl, blood urea nitrogen 100 mg/dl, cre
peak VO2 14 mg·kg
1·min1, 6-min walk test 350 m, no cachexia, no prio
6. Estimate LV reverse remodeling viability on the basis of aggregate clinical data
7. Discuss mitral valve surgery frankly with the patient and family
Issues to discuss: 1) perioperative risk; 2) durability of planned correction; and 3)
long-term LV remodeling and function, and mortality.RT  cardiac resynchronization therapy; LV  left ventricular; MR  mitral regurgitation.Based upon experimental models, overall ventricular re-
odeling parallels myocyte and extracellular matrix remod-
ling. We currently lack, however, sophisticated direct or
ndirect measures of myocyte and matrix remodeling—a
molecular remodeling index”—for clinical use. In the
uture, an integrated approach of biomarker panels (inflam-
ation, oxidative stress, extracellular matrix remodeling,
eurohormonal activation, myocyte injury, and myocyte
tress) (71) complemented by molecular myocardial imaging
66,72,73) and/or endomyocardial biopsy (myocyte number
nd size, myocardial fibrosis, proteomics, and genomics)
74) may refine clinical recommendation.
n integrated approach. A suggested stepwise approach
o clinical management and decision making appears in
able 4. Medical therapy should be optimized for all
atients, with optimization confirmed for selected patients
ith right-side heart catheterization. All suitable candidates
hould undergo CRT. After optimization of medical ther-
py and CRT, the degree of MR should be reassessed. If
R remains severe and the patient remains symptomatic,
hen MV surgery should be considered.
The clinical features informing 1) prognosis; 2) reverse
emodeling viability; 3) perioperative risk; and 4) the antic-
pated durability of repair should all be weighed carefully.
adolinium-enhanced and dobutamine stress MRI may
erify and quantitate MR severity, ventricular dimensions
nd function, fibrosis, and contractile reserve. Ideal opera-
ive candidates posses lesser degrees of LV sphericity and
brosis and possess contractile reserve. For patients for
hom cardiac MRI is not possible, dobutamine stress
chocardiography is reasonable.
A frank discussion should then follow with the patient
egarding the surgical indication, perioperative risk, and
art Failuredvanced Heart Failure
osterone antagonists, flexible sliding-scale diuretic program,
tion functional class III to IV
T with cardiac magnetic resonance imaging or echocardiography
options
l factors
s/min, systolic blood pressure 80 mm Hg with normal proportional pulse
2.5 mg/dl, normal total bilirubin, LV end-diastolic diameter 80 mm,
ac surgery, reversible pulmonary hypertension, no refractory right heart failure
l outcomes on the basis of available data: functional capacity,d Hein A
rs, ald
es
ssocia
and CR
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January 26, 2010:271–82 Mitral Valve Surgery in Advanced HFxpected outcomes. For most patients with advanced HF
nd severe MR, studies to date suggest that MV surgery
hould result in a modest improvement in LV function, a
odest degree of reverse remodeling, and a significant
mprovement in functional capacity by 1 or more NYHA
unctional classes. There is no evidence as yet that MV
urgery in advanced HF reduces mortality.
urgical Considerations
V surgery may be performed via a sternotomy or thora-
otomy. A less invasive right thoracotomy approach may
inimize tissue dissection and inflammation (75–78). A
odified Maze procedure is frequently performed to en-
ance the probability of maintaining normal sinus rhythm.
n patients undergoing MVR or MV replacement, concur-
ent repair of the tricuspid valve by annuloplasty in cases of
evere tricuspid regurgitation associated with dilation of the
ricuspid valve annulus is currently a class I indication (1).
The respective roles of MVR versus MV replacement in
atients with advanced HF continue to evolve. Compared
ith patients undergoing MV replacement with chordal
reservation, patients undergoing MVR have lower perioper-
tive mortality but a higher failure rate (up to 30% at 1 to 2
ears). Because most series to date have reported patients
ndergoing MVR rather than MV replacement, the lack of
emonstrated mortality benefit to date in MV surgery in
dvanced HF may reflect, at least in part, the less durable relief
f MR afforded by MVR rather than MV replacement.
Selected centers combine MV annuloplasty with an
dge-to-edge Alfieri repair to provide more complete MVR
han either technique may provide alone (44). In experi-
nced centers, the edge-to-edge Alfieri repair has been
erformed in instances of mitral leaflet coaptation depth1
m by echocardiography. Although the Alfieri technique
mproves coaptation in instances of MV leaflet flail or
rolapse, it may increase tension on tethered leaflets not
therwise “unstressed” by concurrent annuloplasty (11). The
dge-to-edge repair can restrict the mitral orifice and
otentially lead to mitral stenosis if thickening of the leaflets
s present or develops. Of more concern, the rate of
ecurrent moderate/severe MR has been reported as high as
0% (79).
The normal MV annulus has a saddle-shape configura-
ion, and the resultant increase in leaflet curvature likely
educes leaflet stress (80). By echocardiography and MRI,
atients with MR exhibit flattening of the annulus due to
eduction in the saddle-horn height. Such flattening may
ncrease leaflet closing stress and contribute to MR. Stan-
ard annuloplasty rings are planar and do not conform to
he normal saddle-shaped MV annulus. Development of
-dimensional annuloplasty rings with better conformation
o the saddle-shaped annulus may provide additional reduc-
ion in leaflet closing stress and MR.volving Approaches
iven the central importance of ventricular remodeling,
here is great interest in combining MVR or MV replace-
ent with ventricular remodeling procedures (Table 5).
itral annuloplasty rings continue to evolve. The most
ecent ones are cause specific and geometrically shaped to
ccommodate the underlying pathology, not to replace the
normal” MV annulus (81). A large variety of newer rings
re now available and undergoing clinical evaluation for
heir durability in MVR. Evolving surgical options (11)
nclude such variations in ring annuloplasty design, infarct
r aneurysm plication, excision or exclusion (e.g., Dor
rocedure), external restraint devices (e.g., CorCap), internal
V or papillary muscle “cinching” devices (e.g., CoApsys), pap-
llary muscle repositioning (82), nonbiological material LV
uttressing (83), and leaflet lengthening procedures. Given
he reported failure rates of current annuloplasty techniques,
V remodeling procedures performed in concert with an-
uloplasty will be necessary to provide durable correction in
any patients.
Evolving devices for percutaneous mitral repair fall into 1
f 3 main mechanistic categories: 1) leaflet side-to-side
pposition; 2) annulus cinching; and 3) external restraint
84,85). Such devices, if capable of providing durable results
ith low periprocedural risk, may prove successful nonop-
rative alternatives to MVR.
After successful MV surgery, the remodeling LV may yet
enefit from novel restorative therapies. Overexpression of
ERCA2a by intracoronary gene transfer preserved systolic
unction and improved ventricular remodeling in a porcine
urrent and Evolving Options for Mitralalv Surgery in Advanced Heart FailureTable 5 Current d Evolving Options for MitralValve Surgery in Advanced Heart Failure
1. Mitral repair
Annulus (annuloplasty)
Ring (rigid, flexible; undersized)
Asymmetrical
Percutaneous techniques
Leaflets
Edge-to-edge leaflet (Alfieri)
Leaflet lengthening
Chordae
Basal chordae resection
Papillary muscle
Scar excision with papillary muscle “reimplantation”
Internal slings
Surgical “buckles”
External bands
Mesh patches
Ventricular “reshaping” (with annuloplasty)
Infarct plication
Infarct excision and patching (e.g., Dor)
Localized infarct patch with epicardial balloon
External restraint (e.g., Acorn CorCap)2. Mitral replacement with chordal sparing
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old promise (87).
uture Challenges
iven the heterogeneity of remodeling, it is unlikely that a
one size fits all” option will evolve for the durable correc-
ion of severe MR in patients with advanced HF. Surgeons
nd interventional cardiologists will require a portfolio of
ptions for more targeted, individualized repair of the
nnulus, leaflets, chordae, and the remodeled ventricle.
dherence to criteria similar to those proposed by Lee et al.
52) may afford a more rational approach to the decision
etween repair and replacement based upon pre-operative
chocardiographic criteria. The NHLBI trial in progress
ill provide greater insight into the selection, risks, and
utcomes of MVR versus MV replacement in patients with
schemic MR. Just as more elegant measures of myocardial
iability improved recommendations regarding coronary
evascularization (88), more elegant measures of LV reverse
emodeling viability may improve recommendations for
evere MR in patients with advanced HF. Future measures
f reverse remodeling viability may aggregate biomarkers,
ovel molecular imaging modalities (72,73), and genomic
nd proteomic assays of myocardial tissue.
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